| Literature DB >> 32953031 |
Juan Tang1, Lushun Wang1, Axel Loredo1, Carson Cole1, Han Xiao1,2,3.
Abstract
Photodynamic therapy has become an emerging strategy for the treatment of cancer. This technology relies on the development of photosensitizers (PSs) that convert molecular oxygen to cytotoxic reactive oxygen species upon exposure to light. In this study, we have developed a facile and general strategy for obtaining visible light/near-infrared-absorbing PSs by performing a simple sulfur-for-oxygen replacement within existing fluorophores. Thionation of carbonyl groups within existing fluorophore cores leads to an improvement of the singlet oxygen quantum yield and molar absorption coefficient at longer wavelengths (deep to 600-800 nm). Additionally, these thio-based PSs lack dark cytotoxicity but exhibit significant phototoxicity against monolayer cancer cells and 3D multicellular tumor spheroids with IC50 in the micromolar range. To achieve tumor-specific delivery, we have conjugated these thio-based PSs to an antibody and demonstrated their tumor-specific therapeutic activity. This journal is © The Royal Society of Chemistry 2020.Entities:
Year: 2020 PMID: 32953031 PMCID: PMC7473402 DOI: 10.1039/d0sc02286a
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1Design of thio-based PSs. Thiocarbonyl substitution at the carbonyl group of a variety of fluorophores can dramatically enhance their abilities to generate ROS. Illustrated are structures of the starting (left) and thio-based fluorophores (right) described in this study.
Photophysical and photosensitizing data of thio-based photosensitizers and their oxygen congeners
| PSs |
|
|
|
|
|
| Cou | 261, 378 | 0.95, 2.82 | 445 | 0.71 | — |
| SCou | 273, 476 | 1.43, 2.79 | 453 | <0.001 | 0.64 |
| ACD | 361, 379, 398 | 0.50, 1.0, 1.16 | 406, 428, 455 | 0.64 | — |
| SACD | 430, 456, 485 | 0.52, 1.50, 2.55 | 409, 427, 463 | <0.001 | ∼1 |
| DMAP | 262, 322, 390 | 0.56, 0.28, 0.20 | 505 | 0.09 | — |
| SDMAP | 326, 390, 563 | 3.02, 2.78, 1.02 | 447 | <0.001 | ∼1 |
| DMN | 266, 279, 431 | 1.50, 1.48, 1.08 | 521 | 0.007 | — |
| SDMN | 377, 420, 604 | 0.80, 0.45, 1.48 | — | <0.001 | ∼1 |
| DMNP | 281, 384 | 2.74, 1.71 | 551 | 0.16 | — |
| SDMNP | 264, 388, 586 | 1.77, 1.32, 0.38 | 435 | <0.001 | 0.81 |
| Nile Red | 315, 556 | 0.92, 4.17 | 626 | 0.46 | — |
| SNile Red | 298, 368, 652 | 1.73, 0.97, 4.47 | 616 | <0.001 | 0.36 |
Compounds were dissolved in DMSO (50 μM).
Extinction coefficients.
Fluorescence quantum yields were measured using rhodamine B in ethanol, quinine sulfate in 0.5 M H2SO4 as the reference or fluorescein in 0.1 M NaOH.
Singlet oxygen quantum yields were determined with respect to Ru(bpy)32+ for SCou and SACD (ΦΔ = 0.73 in MeOH)45 and Methylene Blue for SDMAP, SDMN, SDMNP and SNile Red (ΦΔ (MB) = 0.57 in DCM).46 (—), not observed.
Fig. 2(A) Cell viability of HeLa cells after treatment with 3 μM PSs. (B) Cell viability of HeLa cells after treatment with different concentrations of SDMNP in the presence and absence of white light (400–700 nm) or red light (600–630 nm). (C) Confocal images of HeLa MCTS loaded with Calcein AM/PI. Scale bar: 100 μm.
Fig. 3(A) Cell morphological change in the presence or absence of 2 μM SDMNP before or after light irradiation (405 nm laser). Confocal images of HeLa cells loaded with (B) Calcein AM/PI or (C) H2DCFDA. Scale bar: 50 μm. (D) Sodium azide (NaN3) concentration-dependent effect of SDMNP on photocytotoxicity to HeLa cells. *P < 0.005.
Fig. 4(A) Scheme of the antibody-photosensitizer conjugate (Tras-SDMNP) for photoimmunotherapy. (B) Cytotoxicity assays performed with SK-BR-3 and MDA-MB-468 cells with different concentrations of Tras-SDMNP. (C) Cell viability of SK-BR-3 and MDA-MB-468 cells with 0.5 μM Tras-SDMNP after different irradiation times.